SDGR vs SLP
SDGR: Physics-based computational platform that accelerates drug discovery and materials science by predicting molecular properties with high accuracy, enabling faster, cheaper, and more successful drug development. SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry.
Side-by-side fundamentals
| Metric | SDGR | SLP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.03 | $18.25 | |
| Market cap as of 2026-07-23 | $1.1B | $368M | |
| P/E as of 2026-07-23 | n/a | 45.47 | |
| Net margin as of 2026-07-23 | -40.6% | +9.9% | SLP higher |
| Gross margin as of 2026-07-23 | +55.3% | +63.4% | SLP higher |
| Operating margin as of 2026-07-23 | -64.7% | +14.0% | SLP higher |
| ROE as of 2026-07-23 | -30.9% | +6.2% | SLP higher |
| ROA as of 2026-07-23 | -15.3% | +5.7% | SLP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +10.6% | +2.1% | SDGR higher |
| Revenue CAGR (3y) SEC XBRL | +12.2% | +13.7% | SLP higher |
| Dividend yield as of 2026-07-23 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.65 | 1.34 | |
| 1-year return as of 2026-07-22 close | -34.0% | +40.0% | SLP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.